1,697 results on '"Iagnocco A."'
Search Results
2. The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease.
- Author
-
Iagnocco, AnnaMaria, Lioté, Frédéric, McCarthy, Geraldine, Ramonda, Roberta, Richette, Pascal, Sivera, Francisca, Andrés, Mariano, Cipolletta, Edoardo, Doherty, Michael, Pascual, Eliseo, Perez-Ruiz, Fernando, So, Alexander, Jansen, Tim, Kohler, Minna, Stamp, Lisa, Yinh, Janeth, Adinolfi, Antonella, Arad, Uri, Aung, Thanda, Benillouche, Eva, Bortoluzzi, Alessandra, Dau, Jonathan, Maningding, Ernest, Fang, Meika, Figus, Fabiana, Filippucci, Emilio, Haslett, Janine, Janssen, Matthijs, Kaldas, Marian, Kimoto, Maryann, Leamy, Kelly, Navarro, Geraldine, Sarzi-Puttini, Piercarlo, Scirè, Carlo, Silvagni, Ettore, Sirotti, Silvia, Stack, John, Truong, Linh, Abhishek, Abhishek, Tedeschi, Sara, Pascart, Tristan, Latourte, Augustin, Dalbeth, Nicola, Neogi, Tuhina, Fuller, Amy, Rosenthal, Ann, Becce, Fabio, Bardin, Thomas, Ea, Hang-Korng, Filippou, Georgios, Yokose, Chio, Hendry, Alison, Terkeltaub, Robert, Taylor, William, Choi, Hyon, FitzGerald, John, and Xie, Chen
- Subjects
Autoimmune Diseases ,Immune Complex Diseases ,Immune System Diseases ,Humans ,United States ,Chondrocalcinosis ,Rheumatology ,Calcium Pyrophosphate ,Calcinosis ,Syndrome - Abstract
OBJECTIVE: Calcium pyrophosphate deposition (CPPD) disease is prevalent and has diverse presentations, but there are no validated classification criteria for this symptomatic arthritis. The American College of Rheumatology (ACR) and EULAR have developed the first-ever validated classification criteria for symptomatic CPPD disease. METHODS: Supported by the ACR and EULAR, a multinational group of investigators followed established methodology to develop these disease classification criteria. The group generated lists of candidate items and refined their definitions, collected de-identified patient profiles, evaluated strengths of associations between candidate items and CPPD disease, developed a classification criteria framework, and used multi-criterion decision analysis to define criteria weights and a classification threshold score. The criteria were validated in an independent cohort. RESULTS: Among patients with joint pain, swelling, or tenderness (entry criterion) whose symptoms are not fully explained by an alternative disease (exclusion criterion), the presence of crowned dens syndrome or calcium pyrophosphate crystals in synovial fluid are sufficient to classify a patient as having CPPD disease. In the absence of these findings, a score>56 points using weighted criteria, comprising clinical features, associated metabolic disorders, and results of laboratory and imaging investigations, can be used to classify as CPPD disease. These criteria had a sensitivity of 92.2% and specificity of 87.9% in the derivation cohort (190 CPPD cases, 148 mimickers), whereas sensitivity was 99.2% and specificity was 92.5% in the validation cohort (251 CPPD cases, 162 mimickers). CONCLUSION: The 2023 ACR/EULAR CPPD disease classification criteria have excellent performance characteristics and will facilitate research in this field.
- Published
- 2023
3. The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease.
- Author
-
Abhishek, Abhishek, Tedeschi, Sara, Pascart, Tristan, Latourte, Augustin, Dalbeth, Nicola, Neogi, Tuhina, Fuller, Amy, Rosenthal, Ann, Becce, Fabio, Bardin, Thomas, Ea, Hang, Filippou, Georgios, Iagnocco, AnnaMaria, Lioté, Frédéric, McCarthy, Geraldine, Ramonda, Roberta, Richette, Pascal, Sivera, Francisca, Andres, Mariano, Cipolletta, Edoardo, Doherty, Michael, Pascual, Eliseo, Perez-Ruiz, Fernando, So, Alexander, Jansen, Tim, Kohler, Minna, Stamp, Lisa, Yinh, Janeth, Adinolfi, Antonella, Arad, Uri, Aung, Thanda, Benillouche, Eva, Bortoluzzi, Alessandra, Dau, Jonathan, Maningding, Ernest, Fang, Meika, Figus, Fabiana, Filippucci, Emilio, Haslett, Janine, Janssen, Matthijs, Kimoto, Maryann, Leamy, Kelly, Navarro, Geraldine, Sarzi-Puttini, Piercarlo, Scirè, Carlo, Silvagni, Ettore, Sirotti, Silvia, Stack, John, Truong, Linh, Yokose, Chio, Hendry, Alison, Terkeltaub, Robert, Taylor, William, Choi, Hyon, FitzGerald, John, Kaldas, Marian, and Xie, Chen
- Subjects
Humans ,Calcinosis ,Calcium Pyrophosphate ,Chondrocalcinosis ,Rheumatology ,Syndrome ,United States - Abstract
OBJECTIVE: Calcium pyrophosphate deposition (CPPD) disease is prevalent and has diverse presentations, but there are no validated classification criteria for this symptomatic arthritis. The American College of Rheumatology (ACR) and EULAR have developed the first-ever validated classification criteria for symptomatic CPPD disease. METHODS: Supported by the ACR and EULAR, a multinational group of investigators followed established methodology to develop these disease classification criteria. The group generated lists of candidate items and refined their definitions, collected de-identified patient profiles, evaluated strengths of associations between candidate items and CPPD disease, developed a classification criteria framework, and used multi-criterion decision analysis to define criteria weights and a classification threshold score. The criteria were validated in an independent cohort. RESULTS: Among patients with joint pain, swelling, or tenderness (entry criterion) whose symptoms are not fully explained by an alternative disease (exclusion criterion), the presence of crowned dens syndrome or calcium pyrophosphate crystals in synovial fluid are sufficient to classify a patient as having CPPD disease. In the absence of these findings, a score >56 points using weighted criteria, comprising clinical features, associated metabolic disorders, and results of laboratory and imaging investigations, can be used to classify as CPPD disease. These criteria had a sensitivity of 92.2% and specificity of 87.9% in the derivation cohort (190 CPPD cases, 148 mimickers), whereas sensitivity was 99.2% and specificity was 92.5% in the validation cohort (251 CPPD cases, 162 mimickers). CONCLUSION: The 2023 ACR/EULAR CPPD disease classification criteria have excellent performance characteristics and will facilitate research in this field.
- Published
- 2023
4. The effects of suppressing inflammation by tofacitinib may simultaneously improve glycaemic parameters and inflammatory markers in rheumatoid arthritis patients with comorbid type 2 diabetes: a proof-of-concept, open, prospective, clinical study
- Author
-
Di Muzio, Claudia, Di Cola, Ilenia, Shariat Panahi, Azadeh, Ursini, Francesco, Iagnocco, Annamaria, Giacomelli, Roberto, Cipriani, Paola, and Ruscitti, Piero
- Published
- 2024
- Full Text
- View/download PDF
5. Ultrasound as a tool for the diagnosis of spondylarthritis in women
- Author
-
D. Donzella, E. Bellis, and A. Iagnocco
- Subjects
Musculoskeletal ultrasound ,women ,SpA diagnosis ,Medicine ,Internal medicine ,RC31-1245 - Abstract
Objective. The journey to a diagnosis of spondyloarthritis (SpA) can be difficult for women, who often experience delays in receiving the correct diagnosis as their symptoms are frequently misinterpreted due to other conditions like osteoarthritis, fibromyalgia, or other psychosomatic disorders. The purpose of this article is to examine the challenges in the diagnosis of SpA in women and the possible role of musculoskeletal ultrasound in early diagnosis and in avoiding misdiagnosis. Methods. We have performed a narrative review of the currently available literature on the subject. Results. The complexity of diagnosing SpA in women is compounded by the misconception that the disease predominantly affects men. To facilitate early diagnosis and prevent misdiagnosis, it is crucial not to overlook gender differences in the clinical presentation of SpA. Since women have more peripheral and enthesitic involvement, performing an ultrasound of entheses, tendons, and joints in women with musculoskeletal symptoms that could refer to SpA may help both in the early and differential diagnosis. Conclusions. There is a need to increase awareness among physicians of the existence of a different clinical presentation of SpA between men and women. The use of musculoskeletal ultrasound, which allows the detection of even subclinical inflammation and structural damage since early disease at the level of joints, tendons, and entheses can help make an early diagnosis and avoid misdiagnosis. Early diagnosis and timely treatment of SpA are crucial to reducing irreversible damage.
- Published
- 2024
- Full Text
- View/download PDF
6. Correction: Clinical and laboratory features associated with macrophage activation syndrome in Still’s disease: data from the international AIDA Network Still’s Disease Registry
- Author
-
Triggianese, Paola, Vitale, Antonio, Lopalco, Giuseppe, Mayrink Giardini, Henrique Ayres, Ciccia, Francesco, Al-Maghlouth, Ibrahim, Ruscitti, Piero, Sfikakis, Petros Paul, Iannone, Florenzo, de Brito Antonelli, Isabele Parente, Patrone, Martina, Asfina, Kazi Nur, Di Cola, Ilenia, Laskari, Katerina, Gaggiano, Carla, Tufan, Abdurrahman, Sfriso, Paolo, Dagna, Lorenzo, Giacomelli, Roberto, Hinojosa-Azaola, Andrea, Ragab, Gaafar, Fotis, Lampros, Direskeneli, Haner, Spedicato, Veronica, Dagostin, Marilia Ambiel, Iacono, Daniela, Ali, Hebatallah Hamed, Cipriani, Paola, Sota, Jurgen, Kardas, Riza Can, Bindoli, Sara, Campochiaro, Corrado, Navarini, Luca, Gentileschi, Stefano, Martín-Nares, Eduardo, Torres-Ruiz, Jiram, Saad, Moustafa Ali, Kourtesi, Katerina, Alibaz-Oner, Fatma, Sevik, Gizem, Iagnocco, Annamaria, Makowska, Joanna, Govoni, Marcello, Monti, Sara, Maggio, Maria Cristina, La Torre, Francesco, Del Giudice, Emanuela, Hernández-Rodríguez, José, Bartoloni, Elena, Emmi, Giacomo, Chimenti, Maria Sole, Maier, Armin, Simonini, Gabriele, Conti, Giovanni, Olivieri, Alma Nunzia, Tarsia, Maria, De Paulis, Amato, Lo Gullo, Alberto, Więsik-Szewczyk, Ewa, Viapiana, Ombretta, Ogunjimi, Benson, Tharwat, Samar, Erten, Sukran, Nuzzolese, Rossana, Karamanakos, Anastasios, Frassi, Micol, Conforti, Alessandro, Caggiano, Valeria, Marino, Achille, Sebastiani, Gian Domenico, Gidaro, Antonio, Tombetti, Enrico, Carubbi, Francesco, Rubegni, Giovanni, Cartocci, Alessandra, Balistreri, Alberto, Fabiani, Claudia, Frediani, Bruno, and Cantarini, Luca
- Published
- 2024
- Full Text
- View/download PDF
7. Clinical and laboratory features associated with macrophage activation syndrome in Still’s disease: data from the international AIDA Network Still’s Disease Registry
- Author
-
Triggianese, Paola, Vitale, Antonio, Lopalco, Giuseppe, Mayrink Giardini, Henrique Ayres, Ciccia, Francesco, Al-Maghlouth, Ibrahim, Ruscitti, Piero, Sfikakis, Petros Paul, Iannone, Florenzo, de Brito Antonelli, Isabele Parente, Patrone, Martina, Asfina, Kazi Nur, Di Cola, Ilenia, Laskari, Katerina, Gaggiano, Carla, Tufan, Abdurrahman, Sfriso, Paolo, Dagna, Lorenzo, Giacomelli, Roberto, Hinojosa-Azaola, Andrea, Ragab, Gaafar, Fotis, Lampros, Direskeneli, Haner, Spedicato, Veronica, Dagostin, Marilia Ambiel, Iacono, Daniela, Ali, Hebatallah Hamed, Cipriani, Paola, Sota, Jurgen, Kardas, Riza Can, Bindoli, Sara, Campochiaro, Corrado, Navarini, Luca, Gentileschi, Stefano, Martín-Nares, Eduardo, Torres-Ruiz, Jiram, Saad, Moustafa Ali, Kourtesi, Katerina, Alibaz-Oner, Fatma, Sevik, Gizem, Iagnocco, Annamaria, Makowska, Joanna, Govoni, Marcello, Monti, Sara, Maggio, Maria Cristina, La Torre, Francesco, Del Giudice, Emanuela, Hernández-Rodríguez, José, Bartoloni, Elena, Emmi, Giacomo, Chimenti, Maria Sole, Maier, Armin, Simonini, Gabriele, Conti, Giovanni, Olivieri, Alma Nunzia, Tarsia, Maria, De Paulis, Amato, Lo Gullo, Alberto, Więsik-Szewczyk, Ewa, Viapiana, Ombretta, Ogunjimi, Benson, Tharwat, Samar, Erten, Sukran, Nuzzolese, Rossana, Karamanakos, Anastasios, Frassi, Micol, Conforti, Alessandro, Caggiano, Valeria, Marino, Achille, Sebastiani, Gian Domenico, Gidaro, Antonio, Tombetti, Enrico, Carubbi, Francesco, Rubegni, Giovanni, Cartocci, Alessandra, Balistreri, Alberto, Fabiani, Claudia, Frediani, Bruno, and Cantarini, Luca
- Published
- 2023
- Full Text
- View/download PDF
8. The effects of suppressing inflammation by tofacitinib may simultaneously improve glycaemic parameters and inflammatory markers in rheumatoid arthritis patients with comorbid type 2 diabetes: a proof-of-concept, open, prospective, clinical study
- Author
-
Claudia Di Muzio, Ilenia Di Cola, Azadeh Shariat Panahi, Francesco Ursini, Annamaria Iagnocco, Roberto Giacomelli, Paola Cipriani, and Piero Ruscitti
- Subjects
Rheumatoid arthritis ,Type 2 diabetes ,Tofacitinib ,Precision medicine ,Therapy ,Diseases of the musculoskeletal system ,RC925-935 - Abstract
Abstract Background A consistent connection has been increasingly reported between rheumatoid arthritis (RA), insulin resistance (IR), and type 2 diabetes (T2D). The β-cell apoptosis induced by pro-inflammatory cytokines, which could be exaggerated in the context of RA, is associated with increased expression pro-apoptotic proteins, which is dependent on JAnus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) activation. On these bases, we aimed to evaluate if the administration of tofacitinib, a potent and selective JAK inhibitor, could simultaneously improve glycaemic parameters and inflammatory markers in patients with RA and comorbid T2D. Methods The primary endpoint was the change in the 1998-updated homeostatic model assessment of IR (HOMA2-IR) after 6 months of treatment with tofacitinib in RA patients with T2D. Consecutive RA patients with T2D diagnosis were included in this proof-of-concept, open, prospective, clinical study, which was planned before the recent emergence of safety signals about tofacitinib. Additional endpoints were also assessed regarding RA disease activity and metabolic parameters. Results Forty consecutive RA patients with T2D were included (female sex 68.9%, mean age of 63.4 ± 9.9 years). During 6-month follow-up, a progressive reduction of HOMA2-IR was observed in RA patients with T2D treated with tofacitinib. Specifically, a significant effect of tofacitinib was shown on the overall reduction of HOMA2-IR (β = − 1.1, p = 0.019, 95%CI − 1.5 to − 0.76). Also, HOMA2-β enhanced in these patients highlighting an improvement of insulin sensitivity. Furthermore, although a longer follow-up is required, a trend in glycated haemoglobin reduction was also recorded. The administration of tofacitinib induced an improvement in RA disease activity, and a significant reduction of DAS28-CRP and SDAI was observed; 76.8% of patients achieved a good clinical response. In this study, no major adverse events (AEs) were retrieved without the identification of new safety signals. Specifically, no life-threatening AEs and cardiovascular and/or thromboembolic events were recorded. Conclusions The administration of tofacitinib in RA with T2D led to a simultaneous improvement of IR and inflammatory disease activity, inducing a “bidirectional” benefit in these patients. However, further specific designed and powered studies are warranted to entirely evaluate the metabolic effects of tofacitinib in RA patients with T2D.
- Published
- 2024
- Full Text
- View/download PDF
9. Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction.
- Author
-
Tedeschi, Sara, Pascart, Tristan, Latourte, Augustin, Godsave, Cattleya, Kundakci, Burak, Naden, Raymond, Taylor, William, Dalbeth, Nicola, Neogi, Tuhina, Perez-Ruiz, Fernando, Rosenthal, Ann, Becce, Fabio, Pascual, Eliseo, Andres, Mariano, Bardin, Thomas, Doherty, Michael, Ea, Hang-Korng, Filippou, Georgios, Guitierrez, Marwin, Iagnocco, Annamaria, Jansen, Tim, Kohler, Minna, Lioté, Frédéric, Matza, Mark, McCarthy, Geraldine, Ramonda, Roberta, Reginato, Anthony, Richette, Pascal, Singh, Jasvinder, Sivera, Francisca, So, Alexander, Stamp, Lisa, Yinh, Janeth, Yokose, Chio, Choi, Hyon, Abhishek, Abhishek, Terkeltaub, Robert, and FitzGerald, John
- Subjects
Calcium Pyrophosphate ,Chondrocalcinosis ,Crystal Arthropathies ,Humans ,Knee Joint ,Wrist Joint - Abstract
OBJECTIVE: Classification criteria for calcium pyrophosphate deposition (CPPD) disease will facilitate clinical research on this common crystalline arthritis. Our objective was to report on the first 2 phases of a 4-phase process for developing CPPD classification criteria. METHODS: CPPD classification criteria development is overseen by a 12-member steering committee. Item generation (phase I) included a scoping literature review of 5 literature databases and contributions from a 35-member combined expert committee and 2 patient research partners. Item reduction and refinement (phase II) involved a combined expert committee meeting, discussions among clinical, imaging, and laboratory advisory groups, and an item-rating exercise to assess the influence of individual items toward classification. The steering committee reviewed the modal rating score for each item (range -3 [strongly pushes away from CPPD] to +3 [strongly pushes toward CPPD]) to determine items to retain for future phases of criteria development. RESULTS: Item generation yielded 420 items (312 from the literature, 108 from experts/patients). The advisory groups eliminated items that they agreed were unlikely to distinguish between CPPD and other forms of arthritis, yielding 127 items for the item-rating exercise. Fifty-six items, most of which had a modal rating of +/- 2 or 3, were retained for future phases. As numerous imaging items were rated +3, the steering committee recommended focusing on imaging of the knee and wrist and 1 additional affected joint for calcification suggestive of CPP crystal deposition. CONCLUSION: A data- and expert-driven process is underway to develop CPPD classification criteria. Candidate items comprise clinical, imaging, and laboratory features.
- Published
- 2022
10. Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity. Findings from a systematic literature review and experts' consensus
- Author
-
Ruscitti, Piero, Allanore, Yannick, Baldini, Chiara, Barilaro, Giuseppe, Bartoloni Bocci, Elena, Bearzi, Pietro, Bellis, Elisa, Berardicurti, Onorina, Biaggi, Alice, Bombardieri, Michele, Cantarini, Luca, Cantatore, Francesco Paolo, Caporali, Roberto, Caso, Francesco, Cervera, Ricard, Ciccia, Francesco, Cipriani, Paola, Chatzis, Loukas, Colafrancesco, Serena, Conti, Fabrizio, Corberi, Erika, Costa, Luisa, Currado, Damiano, Cutolo, Maurizio, D'Angelo, Salvatore, Del Galdo, Francesco, Di Cola, Ilenia, Di Donato, Stefano, Distler, Oliver, D'Onofrio, Bernardo, Doria, Andrea, Fautrel, Bruno, Fasano, Serena, Feist, Eugen, Fisher, Benjamin A., Gabini, Marco, Gandolfo, Saviana, Gatto, Mariele, Genovali, Irene, Gerli, Roberto, Grembiale, Rosa Daniela, Guggino, Giuliana, Hoffmann-Vold, Anna Maria, Iagnocco, Annamaria, Iaquinta, Francesco Salvatore, Liakouli, Vasiliki, Manoussakis, Menelaos N., Marino, Annalisa, Mauro, Daniele, Montecucco, Carlomaurizio, Mosca, Marta, Naty, Saverio, Navarini, Luca, Occhialini, Daniele, Orefice, Valeria, Perosa, Federico, Perricone, Carlo, Pilato, Andrea, Pitzalis, Costantino, Pontarini, Elena, Prete, Marcella, Priori, Roberta, Rivellese, Felice, Sarzi-Puttini, Piercarlo, Scarpa, Raffaele, Sebastiani, Giandomenico, Selmi, Carlo, Shoenfeld, Yehuda, Triolo, Giovanni, Trunfio, Francesca, Yan, Qingran, Tzioufas, Athanasios G., and Giacomelli, Roberto
- Published
- 2024
- Full Text
- View/download PDF
11. Retention Rate of Ixekizumab in Psoriatic Arthritis: A Real-World Study
- Author
-
Elisa Bellis, Piero Ruscitti, Denise Donzella, Gloria Crepaldi, Valeria Data, Marinella Gammino, Mariele Gatto, Valeria Guardo, Claudia Lomater, Elena Marucco, Marta Saracco, and Annamaria Iagnocco
- Subjects
drug retention rate ,ixekizumab ,psoriatic arthritis ,Medicine - Abstract
We aimed to examine the drug retention rate (DRR) of the interleukin-17 inhibitor ixekizumab in a real-world monocentric cohort of psoriatic arthritis (PsA) patients and to assess the predictors of drug discontinuation. Consecutive PsA patients who underwent treatment with ixekizumab from October 2019 to February 2023 were enrolled in this observational, retrospective, monocentric study. Clinical records were assessed at baseline and throughout the follow-up period. We collected sociodemographic data, smoking habits, body mass index, the presence of Human Leukocyte Antigen B27, comorbidities, disease involvement and duration, previous therapy, discontinuation of ixekizumab, reasons for discontinuation, and adverse events (AEs). DRR was evaluated as time to drug discontinuation and assessed through Kaplan–Meier curves. Baseline factors predicting drug discontinuation were investigated through logistic regression models. Eighty PsA patients were included in this study. Ixekizumab was administered at a dose of 160 mg by subcutaneous injection at baseline, followed by 80 mg every four weeks thereafter. Ixekizumab had a 38-month-cumulative DRR of 43.8%, accounting for both inefficacy and AEs. When considering only inefficacy, the DRR was 62.6%. Comorbidities (p = 0.665), obesity (p = 0.665), smoking (p = 0.884), disease duration ≤ 2 years (p = 0.071), axial (p = 0.131) and skin involvement (p = 0.460), and previous therapies, including conventional synthetic (p = 0.504) and biological (p = 0.474) Disease-Modifying Antirheumatic Drugs (bDMARDs), as well as the number of previous bDMARDs or targeted synthetic Disease-Modifying Antirheumatic Drugs (tsDMARDs), did not significantly affect the DRR (p = 0.349). Multivariate analysis found no independent predictors of drug discontinuation. The most frequent AEs leading to discontinuation were skin reactions; no severe infections were observed. In our real-world study, comorbidities, disease duration, and previous therapies did not affect the DRR of ixekizumab. Ixekizumab had a favorable safety profile, with no severe AEs observed.
- Published
- 2024
- Full Text
- View/download PDF
12. Standardization of interstitial lung disease assessment by ultrasound: results from a Delphi process and web-reliability exercise by the OMERACT ultrasound working group
- Author
-
Delle Sedie, Andrea, Terslev, Lene, Bruyn, George A.W., Cazenave, Tomas, Chrysidis, Stavros, Diaz, Mario, Di Carlo, Marco, Frigato, Marilena, Gargani, Luna, Gutierrez, Marwin, Hocevar, Alojzija, Iagnocco, Annamaria, Juche, Aaron, Keen, Helen, Mandl, Peter, Naredo, Esperanza, Mortada, Mohamed, Pineda, Carlos, Karalilova, Rositsa, Porta, Francesco, Ravagnani, Viviana, Scirè, Carlo, Serban, Teodora, Smith, Kate, Stoenoiu, Maria S., Tardella, Marika, Torralba, Karina, Wakefield, Richard, and D'Agostino, Maria Antonietta
- Published
- 2024
- Full Text
- View/download PDF
13. New onset sarcoidosis following biologic treatment in patients with seronegative inflammatory arthritis: A case series and systematic literature review
- Author
-
Donzella, Denise, Bellis, Elisa, Campisi, Paola, Crepaldi, Gloria, Data, Valeria, Dapavo, Paolo, Lomater, Claudia, Marucco, Elena, Saracco, Marta, Gatto, Mariele, and Iagnocco, Annamaria
- Published
- 2024
- Full Text
- View/download PDF
14. Should ACR/EULAR criteria be revised changing the RF and ACPA scores?
- Author
-
Steiner, Guenter, Van Hoovels, Lieve, Csige, Dóra, Gatto, Mariele, Iagnocco, Annamaria, and Szekanecz, Zoltán
- Published
- 2024
- Full Text
- View/download PDF
15. The Retention Rate and Safety of JAK Inhibitors in Rheumatoid Arthritis: Real Word Data from a Monocentric Cohort
- Author
-
Denise Donzella, Elisa Bellis, Gloria Crepaldi, Valeria Data, Mariele Gatto, Claudia Lomater, Gaetano Liperoti, Elena Marucco, Marta Saracco, and Annamaria Iagnocco
- Subjects
rheumatoid arthritis ,JAK inhibitors ,retention rate ,safety ,real-world data ,Medicine - Abstract
Background/Objectives: To date, the literature concerning real-world data on the retention rate and safety of Janus kinase inhibitors (JAKis) is limited. To retrospectively evaluate the overall drug retention rate (DRR) of different JAKis in a monocentric cohort of patients with rheumatoid arthritis (RA). Methods: Patients diagnosed with RA and treated with JAKis who were evaluated at our outpatient clinic from March 2017 to December 2023 were included in the study. Demographic, clinical characteristics, and comorbidities were recorded. The DRR was evaluated as the time to drug discontinuation, and baseline predictors of drug discontinuation were investigated through Cox regression after adjusting for baseline confounders. Results: The global DRR for JAKis was 51.3%. The DRR was 37.5% for tofacitinib, 46.6% for baricitinib, 69.4% for upadacitinib, and 53.5% for filgotinib. Considering all JAKis, the only significant predictor of drug discontinuation was the use of JAKis as a first-line treatment (HR 95% CI [0.25 (0.13–0.46)]. When considering each JAKi individually, a longer disease duration predicted TOF discontinuation (HR95% CI [1.05 (1.01–1.09)], while seropositivity protected against TOF being withdrawn (HR95% CI [0.41 (0.17–0.97)]. No independent predictors emerged for other JAKis. Conclusions: the use of JAKis as a first-line treatment as well as disease duration and serology may impact the DRR of JAKis, which may inform tailored treatment strategies in clinical practice.
- Published
- 2024
- Full Text
- View/download PDF
16. Efficacy of canakinumab in patients with Still’s disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still’s Disease
- Author
-
Antonio Vitale, Valeria Caggiano, Petros P. Sfikakis, Lorenzo Dagna, Giuseppe Lopalco, Gaafar Ragab, Francesco La Torre, Ibrahim A. Almaghlouth, Maria Cristina Maggio, Jurgen Sota, Abdurrahman Tufan, Andrea Hinojosa-Azaola, Florenzo Iannone, Roberta Loconte, Katerina Laskari, Haner Direskeneli, Piero Ruscitti, Maria Morrone, Henrique A. Mayrink Giardini, Alexandros Panagiotopoulos, Ilenia Di Cola, Eduardo Martín-Nares, Sara Monti, Ludovico De Stefano, Rıza Can Kardas, Rahime Duran, Corrado Campochiaro, Alessandro Tomelleri, Abdulaziz Mohammed Alabdulkareem, Carla Gaggiano, Maria Tarsia, Elena Bartoloni, Mery Romeo, Mohamed A. Hussein, Ahmed Hatem Laymouna, Isabele Parente de Brito Antonelli, Marilia Ambiel Dagostin, Lampros Fotis, Sara Bindoli, Luca Navarini, Fatma Alibaz-Oner, Gizem Sevik, Micol Frassi, Francesco Ciccia, Daniela Iacono, Francesca Crisafulli, Piero Portincasa, Nour Jaber, Perla Ayumi Kawakami-Campos, Ewa Wiesik-Szewczyk, Annamaria Iagnocco, Gabriele Simonini, Paolo Sfriso, Alberto Balistreri, Roberto Giacomelli, Giovanni Conti, Bruno Frediani, Claudia Fabiani, and Luca Cantarini
- Subjects
AOSD ,AutoInflammatory diseases ,rare diseases ,personalized medicine ,treatment ,Medicine (General) ,R5-920 - Abstract
IntroductionThe effectiveness of canakinumab may change according to the different times it is used after Still’s disease onset. This study aimed to investigate whether canakinumab (CAN) shows differences in short- and long-term therapeutic outcomes, according to its use as different lines of biologic treatment.MethodsPatients included in this study were retrospectively enrolled from the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to Still’s disease. Seventy-seven (51 females and 26 males) patients with Still’s disease were included in the present study. In total, 39 (50.6%) patients underwent CAN as a first-line biologic agent, and the remaining 38 (49.4%) patients were treated with CAN as a second-line biologic agent or subsequent biologic agent.ResultsNo statistically significant differences were found between patients treated with CAN as a first-line biologic agent and those previously treated with other biologic agents in terms of the frequency of complete response (p =0.62), partial response (p =0.61), treatment failure (p >0.99), and frequency of patients discontinuing CAN due to lack or loss of efficacy (p =0.2). Of all the patients, 18 (23.4%) patients experienced disease relapse during canakinumab treatment, 9 patients were treated with canakinumab as a first-line biologic agent, and nine patients were treated with a second-line or subsequent biologic agent. No differences were found in the frequency of glucocorticoid use (p =0.34), daily glucocorticoid dosage (p =0.47), or concomitant methotrexate dosage (p =0.43) at the last assessment during CAN treatment.ConclusionCanakinumab has proved to be effective in patients with Still’s disease, regardless of its line of biologic treatment.
- Published
- 2023
- Full Text
- View/download PDF
17. Management of psoriatic arthritis: a consensus opinion by expert rheumatologists
- Author
-
Salvatore D’Angelo, Fabiola Atzeni, Maurizio Benucci, Gerolamo Bianchi, Fabrizio Cantini, Roberto Felice Caporali, Giorgio Carlino, Francesco Caso, Alberto Cauli, Francesco Ciccia, Maria Antonietta D’Agostino, Lorenzo Dagna, Christian Dejaco, Oscar Massimiliano Epis, Maria Grazia Ferrucci, Franco Franceschini, Enrico Fusaro, Marco Gabini, Roberto Gerli, Roberto Giacomelli, Marcello Govoni, Elisa Gremese, Giuliana Guggino, Annamaria Iagnocco, Florenzo Iannone, Bruno Laganà, Ennio Lubrano, Carlomaurizio Montecucco, Rosario Peluso, Roberta Ramonda, Maurizio Rossini, Carlo Salvarani, Gian Domenico Sebastiani, Marco Sebastiani, Carlo Selmi, Enrico Tirri, and Antonio Marchesoni
- Subjects
psoriatic arthritis ,chronic inflammatory musculoskeletal disease ,comorbidities ,extra-articular manifestations ,diagnosis ,treatment ,Medicine (General) ,R5-920 - Abstract
BackgroundPsoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease involving several articular and extra-articular structures. Despite the important progresses recently made in all of the aspects of this disease, its management is still burdened by unresolved issues. The aim of this exercise was to provide a set of statements that may be helpful for the management of PsA.MethodsA group of 38 Italian rheumatologists with recognized expertise in PsA selected and addressed the following four topics: “early PsA,” “axial-PsA,” “extra-articular manifestations and comorbidities,” “therapeutic goals.” Relevant articles from the literature (2016–2022) were selected by the experts based on a PubMed search. A number of statements for each topic were elaborated.ResultsNinety-four articles were selected and evaluated, 68 out of the 1,114 yielded by the literature search and 26 added by the Authors. Each of the four topic was subdivided in themes as follows: transition from psoriasis to PsA, imaging vs. CASPAR criteria in early diagnosis, early treatment for “early PsA”; axial-PsA vs. axialspondyloarthritis, diagnosis, clinical evaluation, treatment, standard radiography vs. magnetic resonance imaging for “axial PsA”; influence of inflammatory bowel disease on the therapeutic choice, cardiovascular comorbidity, bone damage, risk of infection for “comorbidities and extra-articular manifestations”; target and tools, treat-to-target strategy, role of imaging for “therapeutic goals.” The final document consisted of 49 statements.DiscussionThe final product of this exercise is a set of statements concerning the main issues of PsA management offering an expert opinion for some unmet needs of this complex disease.
- Published
- 2023
- Full Text
- View/download PDF
18. Still’s disease continuum from childhood to elderly: data from the international AIDA Network Still’s disease registry
- Author
-
Micol Frassi, Marcello Govoni, Annamaria Iagnocco, Florenzo Iannone, Paola Triggianese, Corrado Campochiaro, Sara Monti, Maria G Tektonidou, Eduardo Martin-Nares, Piero Ruscitti, Roberto Giacomelli, Luca Cantarini, Giuseppe Lopalco, Lorenzo Dagna, Francesco Carubbi, Alma Nunzia Olivieri, Antonio Vitale, Ombretta Viapiana, Fatma Alibaz-Öner, Haner Direskeneli, Petros P Sfikakis, Giacomo Emmi, Claudia Fabiani, Gabriele Simonini, Francesco Ciccia, Elena Bartoloni, Alessandro Tomelleri, Daniela Iacono, Riza Can Kardas, Bruno Frediani, Benson Ogunjimi, Amato de Paulis, Onorina Berardicurti, Alessandro Conforti, Ilenia Di Cola, Anastasios Karamanakos, Katerina Laskari, Abdurrahman Tufan, Stefania Costi, José Hernández-Rodríguez, Lampros Fotis, Jurgen Sota, Antonio Gidaro, Ewa Wiesik-Szewczyk, Gian Domenico Sebastiani, Jiram Torres-Ruiz, Paolo Sfriso, Giovanni Conti, Luca Navarini, Francesco La Torre, Samar Tharwat, Andrea Hinojosa-Azaola, Alberto Lo Gullo, Valeria Caggiano, Ibrahim A Almaghlouth, Kazi Asfina, Gafaar Ragab, Maria Cristina Maggio, Joanna Makowska, Emanuela Del Giudice, Armin Maier, Sukran Erten, Henrique A Mayrink Giardini, Maria Morrone, Isabele Parente de Brito Antonelli, Marilia Ambiel Dagostin, Martina Patrone, Fehaid Alanazi, Carla Gaggiano, Hamit Kucuk, Ayman Abdel-Monem Ahmed Mahmoud, Katerina Kourtesi, Maria Tarsia, Verónica Gómez-Caverzaschi, Angela Mauro, and Alberto Balistreri
- Subjects
Medicine - Abstract
Objective Still’s disease is more frequently observed in the paediatric context, but a delayed onset is not exceptional both in the adulthood and in the elderly. However, whether paediatric-onset, adult-onset and elderly-onset Still’s disease represent expressions of the same disease continuum or different clinical entities is still a matter of controversy. The aim of this study is to search for any differences in demographic, clinical features and response to treatment between pediatric-onset, adult-onset and elderly-onset Still’s disease.Methods Subjects included in this study were drawn from the International AutoInflammatory Disease Alliance Network registry for patients with Still’s disease.Results A total of 411 patients suffering from Still’s disease were enrolled; the disease occurred in the childhood in 65 (15.8%) patients, in the adult 314 (76.4%) patients and in the elderly in 32 (7.8%) patients. No statistically significant differences at post-hoc analysis were observed in demographic features of the disease between pediatric-onset, adult-onset and elderly-onset Still’s disease. The salmon-coloured skin rash (p=0.004), arthritis (p=0.009) and abdominal pain (p=0.007) resulted significantly more frequent among paediatric patients than in adult cases, while pleuritis (p=0.015) and arthralgia (p
- Published
- 2023
- Full Text
- View/download PDF
19. Derivation and validation of four patient clusters in Still’s disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry
- Author
-
Marcello Govoni, Annamaria Iagnocco, Carlomaurizio Montecucco, Sara Monti, Eduardo Martin-Nares, Paola Cipriani, Piero Ruscitti, Roberto Giacomelli, Luca Cantarini, Giuseppe Lopalco, Lorenzo Dagna, Francesco Carubbi, Antonio Vitale, Fatma Alibaz-Öner, Haner Direskeneli, Petros P Sfikakis, Giacomo Emmi, Claudia Fabiani, Gabriele Simonini, Daniele Mauro, Giuliana Guggino, Francesco Ciccia, Elena Bartoloni, Fabiola Atzeni, Daniela Iacono, Ilenia Pantano, Luisa Costa, Francesco Caso, Bruno Frediani, Benson Ogunjimi, Serena Bugatti, Ludovico De Stefano, Onorina Berardicurti, Ilenia Di Cola, Silvia Rossi, Abdurrahman Tufan, José Hernández-Rodríguez, Lampros Fotis, Antonio Gidaro, Jiram Torres-Ruiz, Paolo Sfriso, Luca Navarini, Francesco La Torre, Marco Valenti, Francesco Masedu, Samar Tharwat, Andrea Hinojosa-Azaola, Alberto Lo Gullo, Valeria Caggiano, Claudia Di Muzio, Marcella Prete, Federico Perosa, Henrique Giardini, Isabele Parente de Brito Antonelli, Ibrahim A Almaghlouth, Kazi Asfina, Gizem Sevik, Gafaar Ragab, Maria Cristina Maggio, Joanna Makowska, Emanuela Del Giudice, Armin Maier, and Sukran Erten
- Subjects
Medicine - Abstract
Background Different patient clusters were preliminarily suggested to dissect the clinical heterogeneity in Still’s disease. Thus, we aimed at deriving and validating disease clusters in a multicentre, observational, prospective study to stratify these patients.Methods Patients included in GIRRCS AOSD-study group and AIDA Network Still Disease Registry were assessed if variables for cluster analysis were available (age, systemic score, erythrocyte sedimentation rate (ESR), C reactive protein (CRP) and ferritin). K-means algorithm with Euclidean metric and Elbow plot were used to derive an adequate number of clusters.Results K-means clustering assessment provided four clusters based on means standardised according to z-scores on 349 patients. All clusters mainly presented fever, skin rash and joint involvement. Cluster 1 was composed by 115 patients distinguished by lower values of age and characterised by skin rash myalgia, sore throat and splenomegaly. Cluster 2 included 128 patients identified by lower levels of ESR, ferritin and systemic score; multiorgan manifestations were less frequently observed. Cluster 3 comprised 31 patients categorised by higher levels of CRP and ferritin, they were characterised by fever and joint involvement. Cluster 4 contained 75 patients derived by higher values of age and systemic score. Myalgia, sore throat, liver involvement and life-threatening complications, leading to a high mortality rate, were observed in these patients.Conclusions Four patient clusters in Still’s disease may be recognised by a multidimensional characterisation (‘Juvenile/Transitional’, ‘Uncomplicated’, ‘Hyperferritinemic’ and ‘Catastrophic’). Of interest, cluster 4 was burdened by an increased rate of life-threatening complications and mortality, suggesting a more severe patient group.
- Published
- 2023
- Full Text
- View/download PDF
20. Development and validation of an OMERACT ultrasound scoring system for the extent of calcium pyrophosphate crystal deposition at the joint level and patient level
- Author
-
Sirotti, Silvia, Terslev, Lene, Filippucci, Emilio, Iagnocco, Annamaria, Moller, Ingrid, Naredo, Esperanza, Vreju, Florentin A, Adinolfi, Antonella, Becce, Fabio, Hammer, Hilde Berner, Cazenave, Tomas, Cipolletta, Edoardo, Christiansen, Sara Nysom, Delle Sedie, Andrea, Diaz, Mario, Figus, Fabiana, Mandl, Peter, MacCarter, Daryl, Mortada, Mohamed A, Mouterde, Gael, Porta, Francesco, Reginato, Anthony M, Schmidt, Wolfgang A, Serban, Teodora, Wakefield, Richard J, Zufferey, Pascal, Sarzi-Puttini, Piercarlo, Zanetti, Anna, Damiani, Arianna, Pineda, Carlos, Keen, Helen I, D'Agostino, Maria Antonietta, and Filippou, Georgios
- Published
- 2023
- Full Text
- View/download PDF
21. The administration of methotrexate in patients with Still's disease, “real-life” findings from AIDA Network Still Disease Registry
- Author
-
Ruscitti, Piero, Sota, Jurgen, Vitale, Antonio, Lopalco, Giuseppe, Iannone, Florenzo, Morrone, Maria, Giardini, Henrique Ayres Mayrink, D'Agostin, Marília Ambuel, Antonelli, Isabelle Parente de Brito, AlMaghlouth, Ibrahim, Asfina, Kazi Nur, Khalil, Najma, Sfikakis, Petros P., Laskari, Katerina, Tektonidou, Maria, Ciccia, Francesco, Iacono, Daniela, Riccio, Flavia, Ragab, Gaafar, Hussein, Mohamed A., Govoni, Marcello, Ruffilli, Francesca, Direskeneli, Haner, Alibaz-Oner, Fatma, Giacomelli, Roberto, Navarrini, Luca, Bartoloni, Elena, Riccucci, Ilenia, Martín-Nares, Eduardo, Torres-Ruiz, Jiram, Cipriani, Paola, Cola, Ilenia Di, Hernández-Rodríguez, José, Gómez-Caverzaschi, Verónica, Dagna, Lorenzo, Tomelleri, Alessandro, Makowska, Joanna, Brzezinska, Olga, Iagnocco, Annamaria, Bellis, Elisa, Caggiano, Valeria, Gaggiano, Carla, Tarsia, Maria, Mormile, Ilaria, Emmi, Giacomo, Sfriso, Paolo, Monti, Sara, Erten, Şükran, Giudice, Emanuela Del, Lubrano, Riccardo, Conti, Giovanni, Olivieri, Alma Nunzia, Gullo, Alberto Lo, Tharwat, Samar, Karamanakos, Anastasios, Gidaro, Antonio, Maggio, Maria Cristina, La Torre, Francesco, Cardinale, Fabio, Ogunjimi, Benson, Maier, Armin, Sebastiani, Gian Domenico, Opris-Belinski, Daniela, Frassi, Micol, Viapiana, Ombretta, Bizzi, Emanuele, Carubbi, Francesco, Fotis, Lampros, Tufan, Abdurrahman, Kardas, Riza Can, Więsik-Szewczyk, Ewa, Jahnz-Różyk, Karina, Fabiani, Claudia, Frediani, Bruno, Balistreri, Alberto, Rigante, Donato, and Cantarini, Luca
- Published
- 2023
- Full Text
- View/download PDF
22. Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases
- Author
-
Ursini, Francesco, Ruscitti, Piero, Raimondo, Vincenzo, De Angelis, Rossella, Cacciapaglia, Fabio, Pigatto, Erika, Olivo, Domenico, Di Cola, Ilenia, Galluccio, Felice, Francioso, Francesca, Foti, Rosario, Tavoni, Antonio Gaetano, D’Angelo, Salvatore, Campochiaro, Corrado, Motta, Francesca, De Santis, Maria, Bilia, Silvia, Bruno, Caterina, De Luca, Giacomo, Visentini, Marcella, Ciaffi, Jacopo, Mancarella, Luana, Brusi, Veronica, D’Onghia, Martina, Cuomo, Giovanna, Fusaro, Enrico, Cipriani, Paola, Dagna, Lorenzo, Guiducci, Serena, Meliconi, Riccardo, Iannone, Florenzo, Iagnocco, Annamaria, Giacomelli, Roberto, and Ferri, Clodoveo
- Published
- 2022
- Full Text
- View/download PDF
23. Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce
- Author
-
Laure Gossec, Annamaria Iagnocco, Xenofon Baraliakos, Daniel Aletaha, Josef S Smolen, Alen Zabotti, Dennis G McGonagle, Gabriele De Marco, Jenny Emmel, and Paulo Gisondi
- Subjects
Medicine - Abstract
Background Identifying subjects at risk of imminent psoriatic arthritis (PsA) would allow these subjects to participate in therapeutic interventions to delay or prevent PsA development.Methods A systematic literature review (SLR) was conducted in 2021 in Medline, Embase, PubMed, Central databases and international congress abstracts (PROSPERO CRD42022255102). All articles reporting the characteristics of patients transitioning from psoriasis (PsO) to PsA and from undifferentiated arthritis (UA) to PsA were included. Clinical and imaging characteristics were collated before PsA onset and at time of PsA diagnosis.Results Eighteen of 23 576 references evaluated for PsO/PsA transition were analysed; 14 were cohort studies, 2 case-control studies. Two SLRs were used to enrich the project but were not analysed per se. Of 7873 references focusing on UA to PsA, 3 studies were included. Meta-analysis was not possible due to excessive data heterogeneity. Patients with PsO who developed PsA often reported joint pain, joint tenderness and functional limitations. Arthralgia (PsO, n=669; incident PsA, n=99) was associated with subsequent PsA development. On imaging, subclinical enthesopathy (PsO=325; Incident PsA=39) appeared linked to later PsA development. At the time of PsA onset (incident PsA, N=214), peripheral arthritis, mainly oligo-arthritis (ie, the mean number of swollen joints ranged from 1.5 to 3.2), was the most frequent pattern of clinical presentation.Conclusions Joint pain, arthralgia and entheseal involvement detected by imaging were frequent in individuals with PsO at risk for imminent PsA. Very early PsA was mainly oligoarticular. This review informed a EULAR taskforce on transition to PsA.
- Published
- 2023
- Full Text
- View/download PDF
24. A patient-driven registry on Behçet’s disease: the AIDA for patients pilot project
- Author
-
Carla Gaggiano, Alessandra Del Bianco, Jurgen Sota, Stefano Gentileschi, Piero Ruscitti, Roberto Giacomelli, Matteo Piga, Francesca Crisafulli, Sara Monti, Giacomo Emmi, Amato De Paulis, Antonio Vitale, Maria Tarsia, Valeria Caggiano, Rossana Nuzzolese, Veronica Parretti, Claudia Fabiani, Giuseppe Lopalco, Armin Maier, Marco Cattalini, Donato Rigante, Marcello Govoni, Francesca Li Gobbi, Serena Guiducci, Paola Parronchi, Achille Marino, Francesco Ciccia, Maria Cristina Maggio, Emma Aragona, Elena Bartoloni, Annamaria Iagnocco, Ombretta Viapiana, Gian Domenico Sebastiani, Silvana Guerriero, Antonella Insalaco, Emanuela Del Giudice, Giovanni Conti, Patrizia Barone, Alma Nunzia Olivieri, Antonio Brucato, Francesco Carubbi, Paola Triggianese, Angela Mauro, Gian Marco Tosi, Alex Fonollosa, Henrique Ayres Mayrink Giardini, Gaafar Ragab, Samar Tharwat, José Hernández-Rodríguez, Petros P. Sfikakis, Katerina Laskari, Anastasios Karamanakos, Gerard Espinosa, Farhad Shahram, Haner Direskeneli, Andrea Hinojosa-Azaola, Daniela Opris-Belinski, Ibrahim A. AlMaghlouth, Gülen Hatemi, Mehmet Akif Eksin, Fatos Önen, Ewa Więsik-Szewczyk, Nurullah Akkoç, Abdurrahman Tufan, Ali Şahin, Şükran Erten, Seza Ozen, Ezgi Deniz Batu, Bruno Frediani, Alberto Balistreri, and Luca Cantarini
- Subjects
Behçet’s disease ,patient-driven registries ,rare diseases ,autoinflammatory diseases ,patient involvement ,patient-reported outcomes ,Medicine (General) ,R5-920 - Abstract
IntroductionThis paper describes the creation and preliminary results of a patient-driven registry for the collection of patient-reported outcomes (PROs) and patient-reported experiences (PREs) in Behçet’s disease (BD).MethodsThe project was coordinated by the University of Siena and the Italian patient advocacy organization SIMBA (Associazione Italiana Sindrome e Malattia di Behçet), in the context of the AIDA (AutoInflammatory Diseases Alliance) Network programme. Quality of life, fatigue, socioeconomic impact of the disease and therapeutic adherence were selected as core domains to include in the registry.ResultsRespondents were reached via SIMBA communication channels in 167 cases (83.5%) and the AIDA Network affiliated clinical centers in 33 cases (16.5%). The median value of the Behçet’s Disease Quality of Life (BDQoL) score was 14 (IQR 11, range 0–30), indicating a medium quality of life, and the median Global Fatigue Index (GFI) was 38.7 (IQR 10.9, range 1–50), expressing a significant level of fatigue. The mean Beliefs about Medicines Questionnaire (BMQ) necessity-concern differential was 0.9 ± 1.1 (range – 1.8–4), showing that the registry participants prioritized necessity belief over concerns to a limited extent. As for the socioeconomic impact of BD, in 104 out of 187 cases (55.6%), patients had to pay from their own pocket for medical exams required to reach the diagnosis. The low family socioeconomic status (p
- Published
- 2023
- Full Text
- View/download PDF
25. POS0875 DEFINING THE THRESHOLD OF NORMALITY IN MUSCULOSKELETAL ULTRASOUND; AN OMERACT ULTRASOUND STUDY
- Author
-
Sahbudin, I., primary, Trickey, J., additional, Gouze, H., additional, Stoenoiu, M. S., additional, Filippou, G., additional, Sakellariou, G., additional, Maruseac, M., additional, Wittoek, R., additional, Carron, P., additional, Tinazzi, I., additional, Iagnocco, A., additional, Serban, T., additional, Azzolin, I., additional, Terslev, L., additional, Ammitzbøll-Danielsen, M., additional, Nyhuus Bendix Rasch, M., additional, Hauge, E. M., additional, Hammer, H. B., additional, Milchert, M., additional, Fliciński, J., additional, Mandl, P., additional, Borst, C., additional, Fodor, D., additional, Vreju, F. A., additional, Karalilova, R., additional, Naredo, E., additional, Sifuentes-Cantú, C., additional, La Paglia, G. M. C., additional, Pineda, C., additional, Gutierrez, M., additional, Leon, G., additional, Reátegui-Sokolova, C., additional, Mortada, M. A., additional, Suzuki, T., additional, Ikeda, K., additional, Ciurtin, C., additional, Kortekaas, M., additional, Ohrndorf, S., additional, Keen, H., additional, Bruyn, G., additional, Filer, A., additional, and D’agostino, M. A., additional
- Published
- 2024
- Full Text
- View/download PDF
26. POS1025 ADMINISTRATION OF BELIMUMAB IN EARLY ACTIVE LUPUS PATIENTS HINDERS ACCRUAL OF EULAR/ACR CRITERIA WITHIN THE FIRST 12 MONTHS OF TREATMENT
- Author
-
Gatto, M., primary, Caria, M., additional, Cruciani, C., additional, Pilo, P. F. G., additional, Bellis, E., additional, Donzella, D., additional, Depascale, R., additional, Rossi, D., additional, Roccatello, D., additional, Doria, A., additional, Iagnocco, A., additional, and Sciascia, S., additional
- Published
- 2024
- Full Text
- View/download PDF
27. AB0918 RETENTION RATE OF SECUKINUMAB IN SPONDYLOARTHRITIS: INSIGHTS FROM A REAL-WORLD STUDY
- Author
-
Bellis, E., primary, Gatto, M., additional, Donzella, D., additional, Crepaldi, G., additional, Data, V., additional, DI Gregorio, S., additional, Gammino, M., additional, Guardo, V., additional, Lomater, C., additional, Liperoti, G., additional, Marucco, E., additional, Pastorin, G., additional, Perrone, S., additional, Saracco, M., additional, and Iagnocco, A., additional
- Published
- 2024
- Full Text
- View/download PDF
28. OP0288 OUTCOMES IN PATIENTS WITH SYSTEMIC SCLEROSIS FOLLOWING LUNG TRANSPLANTATION: AN ITALIAN MULTICENTRE EXPERIENCE
- Author
-
Iannone, C., primary, Pellico, M. R., additional, Morlacchi, L. C., additional, Rossetti, V., additional, Vicenzi, M., additional, Trignani, G., additional, Airo’, P., additional, Saracco, M., additional, Iagnocco, A., additional, Beretta, L., additional, Severino, A., additional, Zaccara, E., additional, Cacciapaglia, F., additional, Stano, S., additional, Codullo, V., additional, Meloni, F., additional, Cavalli, S., additional, Minniti, A., additional, Faggioli, P., additional, Blasi, F., additional, Caporali, R. F., additional, and Del Papa, N., additional
- Published
- 2024
- Full Text
- View/download PDF
29. Inflammatory rheumatic diseases with onset after SARS-CoV-2 infection or COVID-19 vaccination: a report of 267 cases from the COVID-19 and ASD group
- Author
-
Laura Massaro, Annamaria Iagnocco, Florenzo Iannone, Corrado Campochiaro, Maria De Santis, Ilaria Cavazzana, Piero Ruscitti, Roberto Giacomelli, Rosario Foti, Lorenzo Dagna, Giovanna Cuomo, Giacomo De Luca, Francesco Caso, Ilenia Di Cola, Clodoveo Ferri, Vincenzo Raimondo, Francesco Ursini, Veronica Brusi, Giuseppe Varcasia, Roberta Pellegrini, Domenico Olivo, Giuseppe Murdaca, Carlo Selmi, Olga Addimanda, Erika Pigatto, Francesca Francioso, Rossella De Angelis, Jacopo Ciaffi, Luana Mancarella, Marcella Visentini, Francesca Motta, Virginia Caira, Alberto Lo Gullo, Caterina Naclerio, Elena Marchetti, Sebastiano Lorusso, Jessica Luppino, Roberta Foti, and Massimo Reta
- Subjects
Medicine - Abstract
Objectives To better define the spectrum of new-onset post-COVID-19 and post-COVID-19 vaccine inflammatory rheumatic diseases (IRD) from a large multicentric observational study.Methods Consecutive cases of IRD encountered during a 12-month period and satisfying one of the following inclusion criteria: (a) onset of the rheumatic manifestations within 4 weeks from SARS-CoV-2 infection or (b) onset of the rheumatic manifestations within 4 weeks from the administration of one of the COVID-19 vaccines ws recruited.Results The final analysis cohort comprised 267 patients, of which 122 (45.2%) in the post-COVID-19 and 145 (54.8%) in the postvaccine cohort. Distribution of IRD categories differed between the two cohorts: the post-COVID-19 cohort had a higher percentage of patients classified as having inflammatory joint diseases (IJD, 52.5% vs 37.2%, p=0.013) while the post-vaccine cohort had a higher prevalence of patients classified as polymyalgia rheumatica (PMR, 33.1% vs 21.3%, p=0.032). No differences were detected in the percentage of patients diagnosed with connective tissue diseases (CTD 19.7% vs 20.7%, p=0.837) or vasculitis (6.6% vs 9.0%, p=0.467). Despite the short follow-up period, IJD and PMR patients’ response to first-line therapy was favourable, with both groups achieving a drop in baseline disease activity scores of ~30% and ~70% respectively.Conclusion Our article reports the largest cohort published to date of new-onset IRD following SARS-CoV-2 infection or COVID-19 vaccines. Although causality cannot be ascertained, the spectrum of possible clinical manifestations is broad and includes IJD, PMR, CTD and vasculitis.
- Published
- 2023
- Full Text
- View/download PDF
30. The specialized pro-resolving lipid mediator Protectin D1 affects macrophages differentiation and activity in Adult-onset Still’s disease and COVID-19, two hyperinflammatory diseases sharing similar transcriptomic profiles
- Author
-
Luca Navarini, Marta Vomero, Damiano Currado, Onorina Berardicurti, Alice Biaggi, Annalisa Marino, Pietro Bearzi, Erika Corberi, Amelia Rigon, Luisa Arcarese, Alessandro Leuti, Marina Fava, Marta Fogolari, Alessia Mattei, Piero Ruscitti, Ilenia Di Cola, Federica Sambuco, Francesco Travaglino, Silvia Angeletti, Francesco Ursini, Erminia Mariani, Paola Cipriani, Felice Eugenio Agrò, Annamaria Iagnocco, Raffaele Antonelli Incalzi, Mauro Maccarrone, and Roberto Giacomelli
- Subjects
Adult-onset Still’s Disease ,COVID-19 ,specialized pro-resolving mediators (SPMs) ,protectin D1 ,hyperinflammation ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionCOVID-19 and autoinflammatory diseases, such as Adult-onset Still’s Disease (AOSD), are characterized by hyperinflammation, in which it is observed massive production and uncontrolled secretion of pro-inflammatory cytokines. The specialized pro-resolving lipid mediators (SPMs) family is one the most important processes counteracting hyperinflammation inducing tissue repair and homeostasis restoration. Among SPMs, Protectin D1 (PD1) is able to exert antiviral features, at least in animal models. The aim of this study was to compare the transcriptome of peripheral blood mononuclear cells (PBMCs) from patients with AOSD and COVID-19 and to evaluate the role of PD1 on those diseases, especially in modulating macrophages polarization.MethodsThis study enrolled patients with AOSD, COVID-19, and healthy donors HDs, undergoing clinical assessment and blood sample collection. Next-generation deep sequencing was performed to identify differences in PBMCs transcripts profiles. Plasma levels of PD1 were assessed by commercial ELISA kits. Monocyte-derived macrophages were polarized into M1 and M2 phenotypes. We analyzed the effect of PD1 on macrophages differentiation. At 10 days, macrophages were analyzed for surface expression of subtypes markers by flow cytometry. Cytokines production was measured in supernatants by Bio-Plex Assays.ResultsIn the transcriptomes from AOSD patients and COVID-19 patients, genes involved in inflammation, lipid catabolism, and monocytes activation were specifically dysregulated in AOSD and COVID-19 patients when compared to HDs. Patients affected by COVID-19, hospitalized in intensive care unit (ICU), showed higher levels of PD1 when compared to not-ICU hospitalized patients and HDs (ICU COVID-19 vs not-ICU COVID-19, p= 0.02; HDs vs ICU COVID-19, p= 0.0006). PD1 levels were increased in AOSD patients with SS ≥1 compared to patients with SS=0 (p=0.028) and HDs (p=0.048). In vitro treatment with PD1 of monocytes-derived macrophages from AOSD and COVID-19 patients induced a significant increase of M2 polarization vs control (p
- Published
- 2023
- Full Text
- View/download PDF
31. Ultrasound as a tool for the diagnosis of spondylarthritis in women.
- Author
-
Donzella, D., Bellis, E., and Iagnocco, A.
- Published
- 2024
- Full Text
- View/download PDF
32. Retention Rate of Ixekizumab in Psoriatic Arthritis: A Real-World Study.
- Author
-
Bellis, Elisa, Ruscitti, Piero, Donzella, Denise, Crepaldi, Gloria, Data, Valeria, Gammino, Marinella, Gatto, Mariele, Guardo, Valeria, Lomater, Claudia, Marucco, Elena, Saracco, Marta, and Iagnocco, Annamaria
- Subjects
HLA-B27 antigen ,ANTIRHEUMATIC agents ,SUBCUTANEOUS injections ,PSORIATIC arthritis ,DISEASE duration - Abstract
We aimed to examine the drug retention rate (DRR) of the interleukin-17 inhibitor ixekizumab in a real-world monocentric cohort of psoriatic arthritis (PsA) patients and to assess the predictors of drug discontinuation. Consecutive PsA patients who underwent treatment with ixekizumab from October 2019 to February 2023 were enrolled in this observational, retrospective, monocentric study. Clinical records were assessed at baseline and throughout the follow-up period. We collected sociodemographic data, smoking habits, body mass index, the presence of Human Leukocyte Antigen B27, comorbidities, disease involvement and duration, previous therapy, discontinuation of ixekizumab, reasons for discontinuation, and adverse events (AEs). DRR was evaluated as time to drug discontinuation and assessed through Kaplan–Meier curves. Baseline factors predicting drug discontinuation were investigated through logistic regression models. Eighty PsA patients were included in this study. Ixekizumab was administered at a dose of 160 mg by subcutaneous injection at baseline, followed by 80 mg every four weeks thereafter. Ixekizumab had a 38-month-cumulative DRR of 43.8%, accounting for both inefficacy and AEs. When considering only inefficacy, the DRR was 62.6%. Comorbidities (p = 0.665), obesity (p = 0.665), smoking (p = 0.884), disease duration ≤ 2 years (p = 0.071), axial (p = 0.131) and skin involvement (p = 0.460), and previous therapies, including conventional synthetic (p = 0.504) and biological (p = 0.474) Disease-Modifying Antirheumatic Drugs (bDMARDs), as well as the number of previous bDMARDs or targeted synthetic Disease-Modifying Antirheumatic Drugs (tsDMARDs), did not significantly affect the DRR (p = 0.349). Multivariate analysis found no independent predictors of drug discontinuation. The most frequent AEs leading to discontinuation were skin reactions; no severe infections were observed. In our real-world study, comorbidities, disease duration, and previous therapies did not affect the DRR of ixekizumab. Ixekizumab had a favorable safety profile, with no severe AEs observed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis
- Author
-
Zabotti, Alen, De Lucia, Orazio, Sakellariou, Garifallia, Batticciotto, Alberto, Cincinelli, Gilberto, Giovannini, Ivan, Idolazzi, Luca, Maioli, Gabriella, Tinazzi, Ilaria, Aletaha, Daniel, De Vita, Salvatore, Marchesoni, Antonio, Smolen, Josef, Iagnocco, Annamaria, McGonagle, Dennis, and Caporali, Roberto
- Published
- 2021
- Full Text
- View/download PDF
34. Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group.
- Author
-
Chrysidis, Stavros, Duftner, Christina, Dejaco, Christian, Schäfer, Valentin, Ramiro, Sofia, Carrara, Greta, Scirè, Carlo, Hocevar, Alojzija, Diamantopoulos, Andreas, Iagnocco, Annamaria, Mukhtyar, Chetan, Ponte, Cristina, Naredo, Esperanza, De Miguel, Eugenio, Bruyn, George, Warrington, Kenneth, Terslev, Lene, Milchert, Marcin, DAgostino, Maria, Koster, Mattew, Rastalsky, Naina, Hanova, Petra, Macchioni, Pierluigi, Kermani, Tanaz, Lorenzen, Tove, Døhn, Uffe, Fredberg, Ulrich, Hartung, Wolfgang, Dasgupta, Bhaskar, and Schmidt, Wolfgang
- Abstract
ObjectivesTo define the elementary ultrasound (US) lesions in giant cell arteritis (GCA) and to evaluate the reliability of the assessment of US lesions according to these definitions in a web-based reliability exercise.MethodsPotential definitions of normal and abnormal US findings of temporal and extracranial large arteries were retrieved by a systematic literature review. As a subsequent step, a structured Delphi exercise was conducted involving an expert panel of the Outcome Measures in Rheumatology (OMERACT) US Large Vessel Vasculitis Group to agree definitions of normal US appearance and key elementary US lesions of vasculitis of temporal and extracranial large arteries. The reliability of these definitions on normal and abnormal blood vessels was tested on 150 still images and videos in a web-based reliability exercise.ResultsTwenty-four experts participated in both Delphi rounds. From originally 25 statements, nine definitions were obtained for normal appearance, vasculitis and arteriosclerosis of cranial and extracranial vessels. The halo and compression signs were the key US lesions in GCA. The reliability of the definitions for normal temporal and axillary arteries, the halo sign and the compression sign was excellent with inter-rater agreements of 91-99% and mean kappa values of 0.83-0.98 for both inter-rater and intra-rater reliabilities of all 25 experts.ConclusionsThe halo and the compression signs are regarded as the most important US abnormalities for GCA. The inter-rater and intra-rater agreement of the new OMERACT definitions for US lesions in GCA was excellent.
- Published
- 2018
35. Validation and incorporation of digital entheses into a preliminary GLobal OMERACT Ultrasound DActylitis Score (GLOUDAS) in psoriatic arthritis
- Author
-
Naredo, Esperanza, primary, D Agostino, Maria Antonietta, additional, Terslev, Lene, additional, Pineda, Carlos, additional, Miguel, M Isabel, additional, Blasi, Joan, additional, Bruyn, George A, additional, Kortekaas, Marion C, additional, Mandl, Peter, additional, Nestorova, Rodina, additional, Szkudlarek, Marcin, additional, Todorov, Plamen, additional, Vlad, Violeta, additional, Wong, Priscilla, additional, Bakewell, Catherine, additional, Filippucci, Emilio, additional, Zabotti, Alen, additional, Micu, Mihaela, additional, Vreju, Florentin, additional, Mortada, Mohamed, additional, Mendonça, José Alexandre, additional, Guillen-Astete, Carlos A, additional, Olivas-Vergara, Otto, additional, Iagnocco, Annamaria, additional, Hanova, Petra, additional, Tinazzi, Ilaria, additional, Balint, Peter V, additional, Aydin, Sibel Zehra, additional, Kane, David, additional, Keen, Helen, additional, Kaeley, Gurjit S, additional, and Möller, Ingrid, additional
- Published
- 2024
- Full Text
- View/download PDF
36. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update
- Author
-
Gossec, Laure, primary, Kerschbaumer, Andreas, additional, Ferreira, Ricardo J O, additional, Aletaha, Daniel, additional, Baraliakos, Xenofon, additional, Bertheussen, Heidi, additional, Boehncke, Wolf-Henning, additional, Esbensen, Bente Appel, additional, McInnes, Iain B, additional, McGonagle, Dennis, additional, Winthrop, Kevin L, additional, Balanescu, Andra, additional, Balint, Peter V, additional, Burmester, Gerd R, additional, Cañete, Juan D, additional, Claudepierre, Pascal, additional, Eder, Lihi, additional, Hetland, Merete Lund, additional, Iagnocco, Annamaria, additional, Kristensen, Lars Erik, additional, Lories, Rik, additional, Queiro, Rubén, additional, Mauro, Daniele, additional, Marzo-Ortega, Helena, additional, Mease, Philip J, additional, Nash, Peter, additional, Wagenaar, Wendy, additional, Savage, Laura, additional, Schett, Georg, additional, Shoop-Worrall, Stephanie J W, additional, Tanaka, Yoshiya, additional, Van den Bosch, Filip E, additional, van der Helm-van Mil, Annette, additional, Zabotti, Alen, additional, van der Heijde, Désirée, additional, and Smolen, Josef S, additional
- Published
- 2024
- Full Text
- View/download PDF
37. A multiparametric risk table for loss of clinical remission status in patients with rheumatoid arthritis: a STARTER study post-hoc analysis
- Author
-
Perniola, Simone, primary, Alivernini, Stefano, additional, Gremese, Elisa, additional, Landolfi, Gianpiero, additional, Carrara, Greta, additional, Iagnocco, Annamaria, additional, and Scirè, Carlo Alberto, additional
- Published
- 2024
- Full Text
- View/download PDF
38. 2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice
- Author
-
Mandl, Peter, primary, D’Agostino, Maria Antonietta, additional, Navarro-Compán, Victoria, additional, Geßl, Irina, additional, Sakellariou, Garifallia, additional, Abhishek, Abhishek, additional, Becce, Fabio, additional, Dalbeth, Nicola, additional, Ea, Hang-Korng, additional, Filippucci, Emilio, additional, Hammer, Hilde Berner, additional, Iagnocco, Annamaria, additional, de Thurah, Annette, additional, Naredo, Esperanza, additional, Ottaviani, Sebastien, additional, Pascart, Tristan, additional, Pérez-Ruiz, Fernando, additional, Pitsillidou, Irene A, additional, Proft, Fabian, additional, Rech, Juergen, additional, Schmidt, Wolfgang A, additional, Sconfienza, Luca Maria, additional, Terslev, Lene, additional, Wildner, Brigitte, additional, Zufferey, Pascal, additional, and Filippou, Georgios, additional
- Published
- 2024
- Full Text
- View/download PDF
39. Ultrasound-detected inflammation is more common in clinically manifest hand osteoarthritis than in painless bony enlarged finger joints: subanalysis of the population-based Bruneck study
- Author
-
Nina Gasperi, Nikolaus Schreiber, Philipp Bosch, Antonella Adinolfi, Arnd Kleyer, Melanie Hagen, Christiane Gasperi, Martin Weger, Stefan Kiechl, Johann Willeit, Georg Schett, Annamaria Iagnocco, Arno Gasperi, Agnes Mayr, and Christian Dejaco
- Subjects
Diseases of the musculoskeletal system ,RC925-935 - Abstract
Purpose: The aim of this article is to examine the extent of structural and inflammatory lesions by ultrasound in elderly subjects with hand osteoarthritis (HOA) fulfilling the ACR classification criteria (Group A), in subjects with painless enlarged finger joints (Group B), and in individuals without clinical abnormalities at hands (Group C). Methods: This study was nested within the population-based, prospective Bruneck study; 293 subjects of ⩾65 years of age were assessed. Clinical and ultrasound assessment was conducted at wrists and finger joints. Gray scale synovitis (GSS), Power Doppler (PD), osteophytes, and erosions were scored semiquantitatively (0–3). The Short Form Score for the Assessment and Quantification of Chronic Rheumatic Affections of the Hands (SF-SACRAH), the Health Assessment Questionnaire (HAQ), and the Functional Index for Hand Osteoarthritis (FIHOA) were retrieved. Results: Most subjects had ⩾1 ultrasound abnormality, of which osteophytes were the most prevalent finding in all groups (Group A: 100%, Group B: 99.4%, and Group C: 93.9%). GSS and PD-signals were more common in Group A than in Group B (94% versus 67% and 33% versus 13%, respectively). In Group C, GSS was observed in 39.4% of subjects. In subjects with HOA, the SF-SACRAH correlated with osteophyte scores (corr coeff = 0.48), and the FIHOA correlated with the osteophyte (corr coeff = 0.42) and PD scores (corr coeff = 0.33). Conclusion: GSS and PD were more frequent in patients with symptomatic HOA than in cases with painless bony enlargements and subjects without clinical joint abnormalities. Functional restriction in HOA is associated with structural and inflammatory ultrasound changes.
- Published
- 2022
- Full Text
- View/download PDF
40. Assessment of health-related quality of life in patients with adult onset Still disease: Results from a multicentre cross-sectional study
- Author
-
Ruscitti, Piero, Rozza, Gelsomina, Di Muzio, Claudia, Biaggi, Alice, Iacono, Daniela, Pantano, Ilenia, Iagnocco, Annamaria, Giacomelli, Roberto, Cipriani, Paola, and Ciccia, Francesco
- Published
- 2022
- Full Text
- View/download PDF
41. The Retention Rate and Safety of JAK Inhibitors in Rheumatoid Arthritis: Real Word Data from a Monocentric Cohort.
- Author
-
Donzella, Denise, Bellis, Elisa, Crepaldi, Gloria, Data, Valeria, Gatto, Mariele, Lomater, Claudia, Liperoti, Gaetano, Marucco, Elena, Saracco, Marta, and Iagnocco, Annamaria
- Subjects
RHEUMATOID arthritis ,DISEASE duration ,RECORDS management ,KINASE inhibitors ,THERAPEUTICS ,ABATACEPT ,GOLIMUMAB - Abstract
Background/Objectives: To date, the literature concerning real-world data on the retention rate and safety of Janus kinase inhibitors (JAKis) is limited. To retrospectively evaluate the overall drug retention rate (DRR) of different JAKis in a monocentric cohort of patients with rheumatoid arthritis (RA). Methods: Patients diagnosed with RA and treated with JAKis who were evaluated at our outpatient clinic from March 2017 to December 2023 were included in the study. Demographic, clinical characteristics, and comorbidities were recorded. The DRR was evaluated as the time to drug discontinuation, and baseline predictors of drug discontinuation were investigated through Cox regression after adjusting for baseline confounders. Results: The global DRR for JAKis was 51.3%. The DRR was 37.5% for tofacitinib, 46.6% for baricitinib, 69.4% for upadacitinib, and 53.5% for filgotinib. Considering all JAKis, the only significant predictor of drug discontinuation was the use of JAKis as a first-line treatment (HR 95% CI [0.25 (0.13–0.46)]. When considering each JAKi individually, a longer disease duration predicted TOF discontinuation (HR95% CI [1.05 (1.01–1.09)], while seropositivity protected against TOF being withdrawn (HR95% CI [0.41 (0.17–0.97)]. No independent predictors emerged for other JAKis. Conclusions: the use of JAKis as a first-line treatment as well as disease duration and serology may impact the DRR of JAKis, which may inform tailored treatment strategies in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Sound therapy in patients with tinnitus: traditional sound generators vs. mobile apps.
- Author
-
ALTISSIMI, G., MUSACCHIO, A., PACE, A., GRECO, A., MAGLIULO, G., IAGNOCCO, G., CIOFALO, A., and RALLI, M.
- Abstract
OBJECTIVE: Tinnitus Retraining Therapy (TRT) is a rehabilitation approach for tinnitus that is currently considered an effective treatment with an elevated response rate. TRT is usually delivered through sound generators; however, they are often difficult to find and expensive. Recently, mobile apps have been proposed for TRT. This study aims to verify the effectiveness of TRT performed using mobile apps in reducing the adverse effects of tinnitus on the quality of life. PATIENTS AND METHODS: A total of 80 patients affected by tinnitus in category 0 (mild tinnitus) and category 1 (moderate tinnitus), according to the Jastreboff classification, were included in the study. Patients of both classes were subsequently differentiated into two homogeneous groups; the first (Group A) was treated with a traditional sound generator, and the second (Group B) using a mobile app. The Tinnitus Handicap Inventory – the Italian version of the questionnaire – was used to investigate the impact of tinnitus on the quality of life in enrolled patients and evaluate their response to TRT. RESULTS: A significant improvement was found in THI scores in category 0 patients for both sound generator and mobile app groups; no difference was found between the two-treatment delivery technology (-1.186, p=0.783); conversely, tinnitus improvements in category 1 patients were only reported for subjects treated using a sound generator (-14.529, p<0.001), while no significant improvement was found in patients treated using the mobile app. CONCLUSIONS: This study confirms the value of TRT, which in patients with mild tinnitus (category 0), can also be delivered through mobile apps with results comparable to traditional sound generators. Further studies are necessary to confirm the effects of the different tinnitus treatments available and improve the knowledge on this topic [ABSTRACT FROM AUTHOR]
- Published
- 2024
43. Correction: Clinical and laboratory features associated with macrophage activation syndrome in Still’s disease: data from the international AIDA Network Still’s Disease Registry
- Author
-
Triggianese, Paola, primary, Vitale, Antonio, additional, Lopalco, Giuseppe, additional, Mayrink Giardini, Henrique Ayres, additional, Ciccia, Francesco, additional, Al-Maghlouth, Ibrahim, additional, Ruscitti, Piero, additional, Sfikakis, Petros Paul, additional, Iannone, Florenzo, additional, de Brito Antonelli, Isabele Parente, additional, Patrone, Martina, additional, Asfina, Kazi Nur, additional, Di Cola, Ilenia, additional, Laskari, Katerina, additional, Gaggiano, Carla, additional, Tufan, Abdurrahman, additional, Sfriso, Paolo, additional, Dagna, Lorenzo, additional, Giacomelli, Roberto, additional, Hinojosa-Azaola, Andrea, additional, Ragab, Gaafar, additional, Fotis, Lampros, additional, Direskeneli, Haner, additional, Spedicato, Veronica, additional, Dagostin, Marilia Ambiel, additional, Iacono, Daniela, additional, Ali, Hebatallah Hamed, additional, Cipriani, Paola, additional, Sota, Jurgen, additional, Kardas, Riza Can, additional, Bindoli, Sara, additional, Campochiaro, Corrado, additional, Navarini, Luca, additional, Gentileschi, Stefano, additional, Martín-Nares, Eduardo, additional, Torres-Ruiz, Jiram, additional, Saad, Moustafa Ali, additional, Kourtesi, Katerina, additional, Alibaz-Oner, Fatma, additional, Sevik, Gizem, additional, Iagnocco, Annamaria, additional, Makowska, Joanna, additional, Govoni, Marcello, additional, Monti, Sara, additional, Maggio, Maria Cristina, additional, La Torre, Francesco, additional, Del Giudice, Emanuela, additional, Hernández-Rodríguez, José, additional, Bartoloni, Elena, additional, Emmi, Giacomo, additional, Chimenti, Maria Sole, additional, Maier, Armin, additional, Simonini, Gabriele, additional, Conti, Giovanni, additional, Olivieri, Alma Nunzia, additional, Tarsia, Maria, additional, De Paulis, Amato, additional, Lo Gullo, Alberto, additional, Więsik-Szewczyk, Ewa, additional, Viapiana, Ombretta, additional, Ogunjimi, Benson, additional, Tharwat, Samar, additional, Erten, Sukran, additional, Nuzzolese, Rossana, additional, Karamanakos, Anastasios, additional, Frassi, Micol, additional, Conforti, Alessandro, additional, Caggiano, Valeria, additional, Marino, Achille, additional, Sebastiani, Gian Domenico, additional, Gidaro, Antonio, additional, Tombetti, Enrico, additional, Carubbi, Francesco, additional, Rubegni, Giovanni, additional, Cartocci, Alessandra, additional, Balistreri, Alberto, additional, Fabiani, Claudia, additional, Frediani, Bruno, additional, and Cantarini, Luca, additional
- Published
- 2023
- Full Text
- View/download PDF
44. Efficacy of canakinumab in patients with Still’s disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still’s Disease
- Author
-
Vitale, Antonio, primary, Caggiano, Valeria, additional, Sfikakis, Petros P., additional, Dagna, Lorenzo, additional, Lopalco, Giuseppe, additional, Ragab, Gaafar, additional, La Torre, Francesco, additional, Almaghlouth, Ibrahim A., additional, Maggio, Maria Cristina, additional, Sota, Jurgen, additional, Tufan, Abdurrahman, additional, Hinojosa-Azaola, Andrea, additional, Iannone, Florenzo, additional, Loconte, Roberta, additional, Laskari, Katerina, additional, Direskeneli, Haner, additional, Ruscitti, Piero, additional, Morrone, Maria, additional, Mayrink Giardini, Henrique A., additional, Panagiotopoulos, Alexandros, additional, Di Cola, Ilenia, additional, Martín-Nares, Eduardo, additional, Monti, Sara, additional, De Stefano, Ludovico, additional, Kardas, Rıza Can, additional, Duran, Rahime, additional, Campochiaro, Corrado, additional, Tomelleri, Alessandro, additional, Alabdulkareem, Abdulaziz Mohammed, additional, Gaggiano, Carla, additional, Tarsia, Maria, additional, Bartoloni, Elena, additional, Romeo, Mery, additional, Hussein, Mohamed A., additional, Laymouna, Ahmed Hatem, additional, Parente de Brito Antonelli, Isabele, additional, Dagostin, Marilia Ambiel, additional, Fotis, Lampros, additional, Bindoli, Sara, additional, Navarini, Luca, additional, Alibaz-Oner, Fatma, additional, Sevik, Gizem, additional, Frassi, Micol, additional, Ciccia, Francesco, additional, Iacono, Daniela, additional, Crisafulli, Francesca, additional, Portincasa, Piero, additional, Jaber, Nour, additional, Kawakami-Campos, Perla Ayumi, additional, Wiesik-Szewczyk, Ewa, additional, Iagnocco, Annamaria, additional, Simonini, Gabriele, additional, Sfriso, Paolo, additional, Balistreri, Alberto, additional, Giacomelli, Roberto, additional, Conti, Giovanni, additional, Frediani, Bruno, additional, Fabiani, Claudia, additional, and Cantarini, Luca, additional
- Published
- 2023
- Full Text
- View/download PDF
45. The Novel OMERACT Ultrasound Scoring System for Salivary Gland Changes in Patients With Sjögren Syndrome Is Associated With MRI and Salivary Flow Rates
- Author
-
Inanc, Nevsun, primary, Jousse-Joulin, Sandrine, additional, Abacar, Kerem, additional, Cimşit, Çagatay, additional, Cimşit, Canan, additional, D'Agostino, Maria-Antonietta, additional, Naredo, Esperanza, additional, Hocevar, Alojzija, additional, Finzel, Stephanie, additional, Pineda, Carlos, additional, Keen, Helen, additional, Iagnocco, Annamaria, additional, Hanova, Petra, additional, Schmidt, Wolfgang A., additional, Mumcu, Gonca, additional, Terslev, Lene, additional, and Bruyn, George A., additional
- Published
- 2023
- Full Text
- View/download PDF
46. New onset sarcoidosis following biologic treatment in patients with seronegative inflammatory arthritis: A case series and systematic literature review
- Author
-
Donzella, Denise, primary, Bellis, Elisa, additional, Campisi, Paola, additional, Crepaldi, Gloria, additional, Data, Valeria, additional, Dapavo, Paolo, additional, Lomater, Claudia, additional, Marucco, Elena, additional, Saracco, Marta, additional, Gatto, Mariele, additional, and Iagnocco, Annamaria, additional
- Published
- 2023
- Full Text
- View/download PDF
47. Derivation and validation of four patient clusters in Still’s disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry
- Author
-
Ruscitti, Piero, primary, Masedu, Francesco, additional, Vitale, Antonio, additional, Di Cola, Ilenia, additional, Caggiano, Valeria, additional, Di Muzio, Claudia, additional, Cipriani, Paola, additional, Valenti, Marco, additional, Berardicurti, Onorina, additional, Navarini, Luca, additional, Iacono, Daniela, additional, Pantano, Ilenia, additional, Mauro, Daniele, additional, Ciccia, Francesco, additional, Rossi, Silvia, additional, De Stefano, Ludovico, additional, Monti, Sara, additional, Bugatti, Serena, additional, Montecucco, Carlomaurizio, additional, Caso, Francesco, additional, Costa, Luisa, additional, Prete, Marcella, additional, Perosa, Federico, additional, Iagnocco, Annamaria, additional, Atzeni, Fabiola, additional, Guggino, Giuliana, additional, Giardini, Henrique, additional, Antonelli, Isabele Parente de Brito, additional, Almaghlouth, Ibrahim A, additional, Asfina, Kazi, additional, Direskeneli, Haner, additional, Alibaz-Oner, Fatma, additional, Sevik, Gizem, additional, Tufan, Abdurrahman, additional, Sfikakis, Petros P, additional, La Torre, Francesco, additional, Hinojosa-Azaola, Andrea, additional, Martín-Nares, Eduardo, additional, Torres-Ruiz, Jiram, additional, Ragab, Gafaar, additional, Maggio, Maria Cristina, additional, Makowska, Joanna, additional, Del Giudice, Emanuela, additional, Bartoloni, Elena, additional, Emmi, Giacomo, additional, Govoni, Marcello, additional, Lo Gullo, Alberto, additional, Lopalco, Giuseppe, additional, Simonini, Gabriele, additional, Fotis, Lampros, additional, Ogunjimi, Benson, additional, Tharwat, Samar, additional, Frediani, Bruno, additional, Maier, Armin, additional, Carubbi, Francesco, additional, Dagna, Lorenzo, additional, Erten, Sukran, additional, Gidaro, Antonio, additional, Hernández-Rodríguez, José, additional, Sfriso, Paolo, additional, Fabiani, Claudia, additional, Giacomelli, Roberto, additional, and Cantarini, Luca, additional
- Published
- 2023
- Full Text
- View/download PDF
48. L’échographie en mode doppler couleur a-t-elle changé l’approche diagnostique de l’artérite à cellules géantes? Comparaison avec la biopsie de l’artère temporale
- Author
-
Bellis, Elisa, primary, Donzella, Denise, additional, Navarini, Luca, additional, Giacomelli, Roberto, additional, and Iagnocco, Annamaria, additional
- Published
- 2023
- Full Text
- View/download PDF
49. Dynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study
- Author
-
Cimmino MA, Parodi M, Barbieri F, Bombardieri S, Zampogna G, Iagnocco A, Batticciotto A, Sconfienza LM, Sinigaglia L, De Benedetti F, Atzeni F, and Sarzi-Puttini P
- Subjects
tocilizumab ,rheumatoid arthritis ,wrist ,synovitis ,low-field mri ,dedicated mri ,Medicine (General) ,R5-920 - Abstract
Marco A Cimmino,1 Massimiliano Parodi,1 Francesca Barbieri,1 Stefano Bombardieri,2 Giuseppe Zampogna,1 Annamaria Iagnocco,3 Alberto Batticciotto,4 Luca Maria Sconfienza,5,6 Luigi Sinigaglia,7 Fabrizio De Benedetti,8 Fabiola Atzeni,9 Piercarlo Sarzi-Puttini10 1Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy; 2Rheumatology Unit, Santa Chiara Hospital, University of Pisa, Pisa, Italy; 3Academic Rheumatology Centre, Università degli Studi di Torino, Turin, Italy; 4Rheumatology Unit ASST-Settelaghi, Ospedale di Circolo – Fondazione Macchi, Varese, Varese, Italy; 5IRCCS Istituto Ortopedico Galeazzi, Milan, Italy; 6Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Milan, Italy; 7Rheumatology Unit, G. Pini Hospital, Milan, Italy; 8Division of Rheumatology, IRCCS, Bambin Gesù Paediatric Hospital, Rome, Italy; 9Rheumatology Unit, University of Messina, Messina, Italy; 10Rheumatology Unit, L. Sacco University Hospital, Milan, ItalyCorrespondence: Piercarlo Sarzi-PuttiniReumatology Department, L. Sacco University Hospital, ASST Fatebenefratelli – Sacco, Via G.B. Grassi, 74, Milan 20157, ItalyTel +39 02 39042208Email piercarlo.sarziputtini@gmail.comObjective: This open-label study evaluated the effects of combined tocilizumab (TCZ) and disease-modifying antirheumatic drugs (DMARDs) on magnetic resonance imaging (MRI) changes in synovial membrane enhancement, bone marrow edema (BME), and erosions in the wrist and hand joints of rheumatoid arthritis (RA) patients inadequately responding to DMARDs alone.Methods: The efficacy of intravenous TCZ 8 mg/kg administered every four weeks for 48 weeks was evaluated on six occasions. The primary endpoints were the changes in the extent and degree of wrist synovitis as measured using the RA MRI Score (RAMRIS) and dynamic, gadolinium-enhanced 0.2T MRI (DCE-MRI). A number of different parameters of DCE-MRI were evaluated.Results: Fifty-eight patients were treated, eight of whom (13.8%) discontinued the study prematurely. The mean RAMRIS significantly decreased after two weeks and the decrease was maintained for up to 48 weeks. By week 4, the mean RAMRIS synovitis score had significantly decreased from baseline (− 0.804± 1.575; p=0.018), but not the mean early enhancement (REE) or relative enhancement (RE). However, there were significant decreases in RE at week 24, in REE and Ntotal (total number of enhancing voxels)*IRE (initial rate of enhancement) at weeks 12, 24 and 48, and in Ntotal*ME (maximal enhancement) at weeks 24 and 48. Mean BME decreased from baseline to week 48, and bone erosions did not progress. The patients’ clinical parameters significantly improved from baseline until week 48.Conclusion: TCZ in combination with DMARDs improved wrist synovitis, BME and clinical parameters, without any progression in bone erosions. The RAMRIS for synovitis rapidly improved from as early as two weeks after the first TCZ infusion. (Funded by F. Hoffmann–La Roche; ACTRACE EudraCT No. 2009 012185-32).Keywords: tocilizumab, rheumatoid arthritis, wrist, synovitis, low-field MRI, dedicated MRI
- Published
- 2020
50. Nail ultrasonography for psoriatic arthritis and psoriasis patients: a systematic literature review
- Author
-
Fassio, A., Giovannini, I., Idolazzi, L., Zabotti, A., Iagnocco, A., and Sakellariou, G.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.